Sun Pharma Advanced Research Company Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Sun Pharma Advanced Research Company has allotted 3,85,10,000 warrants to Shanghvi Finance at an issue price of Rs 155.80/- per warrant on preferential basis, out of which the Company has received an amount of Rs 149.99 crore which is equivalent to 25% of the warrant issue price.

Each of the Warrant, so allotted, is convertible into or exchangeable for one fully paid-up equity share of face value of Re 1/- of the Company in accordance with the provisions of SEBI ICDR Regulations.

Net profit of Sun Pharma Advanced Research Company reported to Rs 1761.34 crore in the quarter ended March 2026 as against net loss of Rs 59.77 crore during the previous quarter ended March 2025. Sales declined 51.45% to Rs 13.20 crore in the quarter ended March 2026 as against Rs 27.19 crore during the previous quarter ended March 2025.

For the full year,net profit reported to Rs 1553.20 crore in the year ended March 2026 as against net loss of Rs 342.51 crore during the previous year ended March 2025. Sales declined 45.45% to Rs 39.15 crore in the year ended March 2026 as against Rs 71.77 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 18 May 2026.

Sun Pharma Advanced Research Company (SPARC) has entered into a definitive asset purchase agreement to sell its Rare Paediatric Disease Priority Review Voucher (PRV) for US $195 million upon the closing of the transaction.

PRV was granted by the U.S. Food and Drug Administration (FDA) for the approval of Sezaby? indicated for the treatment of neonatal seizures.

?The sale of the PRV will enable us to accelerate the development of our pipeline assets and strengthen our external innovation strategy, which has already delivered multiple additions to our portfolio,? said Anil Raghavan, CEO of SPARC. The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act.

Stifel acted as the exclusive financial advisor to SPARC with respect to this transaction.